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Unlike for septic shock, there are no specific international recommendations regarding the management of cardiogenic
shock (CS) in critically ill patients. We present herein recommendations for the management of cardiogenic shock in
adults, developed with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system by
an expert group of the French-Language Society of Intensive Care (Société de Réanimation de Langue Française (SRLF)),
with the participation the French Society of Anesthesia and Intensive Care (SFAR), the French Cardiology Society (SFC),
the French Emergency Medicine Society (SFMU), and the French Society of Thoracic and Cardiovascular Surgery
(SFCTCV). The recommendations cover 15 fields of application such as: epidemiology, myocardial infarction, monitoring,
vasoactive drugs, prehospital care, cardiac arrest, mechanical assistance, general treatments, cardiac surgery, poisoning,
cardiogenic shock complicating end-stage cardiac failure, post-shock treatment, various etiologies, and medical care
pathway. The experts highlight the fact that CS is a rare disease, the management of which requires a multidisciplinary
technical platform as well as specialized and experienced medical teams. In particular, each expert center must be able
to provide, at the same site, skills in a variety of disciplines, including medical and interventional cardiology, anesthesia,
thoracic and vascular surgery, intensive care, cardiac assistance, radiology including for interventional vascular
procedures, and a circulatory support mobile unit.
Keywords: Cardiogenic shock; Myocardial infarction; Monitoring; Extracorporeal membrane oxygenationReview
Introduction
Contrary to septic shock, there are no international
recommendations regarding the management of cardio-
genic shock (CS) in intensive care. Reasons include the
rarity of the disease, but also the fact that patients with CS
often solely receive care in cardiology. Recent European
Society of Cardiology (ESC) guidelines on the manage-
ment of acute heart failure include a section on CS [1].
However, these guidelines are vague for the intensivist and
at times obsolete (with regard to vasopressors, for example).
The lack of a specific approach to the management of severe* Correspondence: blevy5463@gmail.com
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provided the original work is properly creditedforms of CS in the latest international guidelines led our
group to draw the following recommendations. The expert
panel also deemed of interest to take into consideration the
care spectrum for these specific patients, by emphasizing
the notion of expertise.
Methodology
These recommendations were drawn by an expert panel
convened by the French Intensive Care Society (SRLF).
The various disciplines contributing to the management
of CS in adults were represented as follows: intensive
care, anesthesia, cardiac surgery, cardiology, and emer-
gency medicine. The organizing committee first defined,
with the coordinator of the expert panel, the issues to be
covered and then designated the experts in charge of
each issue. The GRADE (Grading of Recommendations
Assessment, Development and Evaluation) system and ale distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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mendations [2]. A level of proof was defined for each
bibliographic reference depending on the type of study.
This level of proof could be reassessed taking into ac-
count the methodological quality of the study. The bib-
liographic references common to each assessment
criterion were then combined. An overall level of proof
was determined for each assessment criterion taking into
account the levels of proof of each of the references, the
consistency of the results between the different studies,
the direct or indirect nature of the proof, the cost ana-
lysis, etc. A “strong” level of proof enabled formulation
of a “strong” recommendation (should be performed,
should not be performed, etc.). A “moderate”, “weak”, or
“very weak” level of proof led to the formulation of an
“optional” recommendation (should probably be per-
formed, should probably not be performed, etc.). The pro-
posed recommendations were presented and discussed
one by one. The aim was not necessarily to reach a single
and convergent opinion for all proposals, but rather to
highlight points of agreement and points of disagreement
or indecision. Each recommendation was then scored by
each of the experts on a scale of one (complete disagree-
ment) to nine (complete agreement). The collective scoring
was established using a methodology derived from the
RAND/UCLA appropriateness method; after elimination
of the extreme values (outliers), the median of values at-
tributed to each proposed recommendation defined
agreement between the experts when the median value
was between seven and nine, disagreement between
one and three, and indecision between four and six.
The agreement, disagreement, or indecision was
“strong” if all values were within one of the following
three ranges, (1–3), (4–6), or (7–9), and “weak” if the
range of values straddled two ranges. In the absence of
strong agreement, the recommendations were reformu-
lated and again scored with the purpose of achieving a
better consensus.Cardiogenic shock definition
Cardiogenic shock (CS) is defined as a state of critical
end-organ hypoperfusion due to reduced cardiac output.
Notably, CS forms a spectrum ranging from mild hypo-
perfusion to profound shock.
Established criteria for the diagnosis of CS are as
follows: (1) systolic blood pressure less than 90 mmHg
for 30 min or mean arterial pressure less than 65 mmHg
for 30 min or vasopressors required to achieve a blood
pressure ≥90 mmHg; (2) pulmonary congestion or elevated
left-ventricular filling pressures; (3) signs of impaired organ
perfusion with at least one of the following criteria: (a)
altered mental status; (b) cold, clammy skin; (c) oliguria;
(d) increased serum lactate.Area 1: epidemiology
1- In cardiogenic shock, a coronary cause should
routinely be sought (strong agreement).
In over 70 % of cases, CS is related to acute myocardial
infarction (MI) with ST-segment elevation, with or without
mechanical complications (rupture of the septum, of the
ventricular wall or of chordae tendineae). However, shock
rarely occurs during MI (4.2 to 8.6 % of cases, depending
on the study) and is declining [3]. ECG, troponin assay (re-
peated if necessary), and natriuretic peptide assay should
be performed routinely, and coronary angiography should
be considered. Patients in shock or with a high risk of CS
should be hospitalized, preferably in intensive care. Except
for patients with ventricular assistance, CS is associated
with an immediate mortality of approximately 40 % [4].
Survivors have a very good prognosis, with a very good
quality of life.Area 2: cardiogenic shock in acute myocardial infarction
1- Predictors of progression to cardiogenic shock, in
particular a heart rate >75 beats/min and signs of
heart failure, should be sought in all patients with
myocardial infarction (strong agreement).
In two-thirds of cases, shock is not present at admission
and occurs in the first 48 h following admission for MI [5].
The predictors of ischemic CS are age, heart rate on admis-
sion above 75 beats/min, diabetes, history of MI, coronary
artery-bypass surgery, the presence of signs of heart failure
at admission, and anterior location of the infarction [6].
2- Coronary angiography, followed by coronary
revascularization using angioplasty or exceptionally
coronary artery-bypass surgery, is required in
cardiogenic shock secondary to acute myocardial
infarction irrespective of the time interval since the
onset of pain (strong agreement).
The SHOCK trial conducted from April 1993 to
November 1998 in 30 centers, and the associated regis-
try assessed the effects of early revascularization (angio-
plasty or coronary artery-bypass surgery performed in
the first 6 h) compared with stabilization by medical
treatment in patients hospitalized for post-myocardial
infarction CS. Whereas mortality at 30 days did not
differ significantly in the early revascularization group
compared with the control group (46.7 vs. 56 %) [7],
early revascularization reduced mortality at 1 year (50.3
vs. 63.1 %, p = 0.027) [8] and 6 years [9]. The SHOCK
trial showed no benefit of revascularization in the over-
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by the small number of patients. (Certain, Some) regis-
tries suggest a benefit of revascularization in patients
over 75 years of age.
Despite the fact that early revascularization is more
efficient and given that CS secondary to MI has a poor
prognosis, the ESC guidelines on MI recommend revascu-
larization regardless of the time interval since the onset of
the infarction. The ESC guidelines suggest the use of
thrombolysis if angioplasty cannot be performed quickly
(within 2 h), with secondary transfer to a center with a
coronary angioplasty and cardiac surgery unit [10].
Intensive care before coronary angiography of CS
secondary to MI should be of the “scoop and run” type.
What is important is to transfer the patient alive to the
coronary angiography unit without any delay as a result
of an attempt at stabilization.
3- Cardiogenic shock secondary to acute myocardial
infarction (MI) or MI likely to progress to
cardiogenic shock should be managed in expert
centers with a department of interventional
cardiology and cardiac surgery fully equipped with
cardiac support or in a coronary angioplasty center
working in network with an expert center so as to
plan a possible secondary transfer after emergency
revascularization (strong agreement).
Patients presenting CS secondary to MI will generally
receive multidisciplinary care. Coronary angioplasty is
the reference treatment. Cardiac surgery is an integral
part of the treatment of post-MI CS, through emergency
bypass surgery, treatment of mechanical complications,
or possible implantation of cardiac assistance devices. It
is therefore desirable to transfer patients with post-MI
CS or with MI plus predictors of secondary CS to an ex-
pert center, ideally one that offers interventional cardi-
ology, cardiac surgery with the possibility of cardiac
support, and even heart transplantation. If the distance
is too great (>2 h between the first contact and artery
clearing), patients with post-MI CS or with MI plus signs
of CS should be transferred to an interventional cardi-
ology department without cardiac surgery that works in
network with an expert center, so as to plan any secondary
transport needed after emergency angioplasty.
Area 3: monitoring in intensive care
1- An arterial catheter should be placed to monitor
blood pressure (strong agreement).
The arterial catheter provides a continuous reading of
diastolic arterial pressure (DAP), the driving pressure dur-
ing relaxation and dilatation of the ventricles when fillingwith blood. DAP is influenced by peripheral arterial tone,
heart rate, and arterial compliance. In a patient without
bradycardia, low DAP is generally linked to a drop in arter-
ial tone and calls for the use of a vasopressor or an increase
in its dosage if mean arterial pressure is <65 mmHg.
2- Plasma lactate should be assayed repeatedly
(in the absence of epinephrine therapy) to assess the
persistence or correction of shock during treatment
(strong agreement).
3- Organ function markers should be repeatedly
checked (kidney, liver) (strong agreement).
4- A central venous catheter placed in the superior vena
cava should be used for intermittent (blood sample)
or continuous (fiber optic) measurement of central
venous oxygen saturation (ScvO2) (strong agreement).
Inasmuch as central venous catheterization is mandatory
in shock, particularly in cardiogenic shock, use of this
catheter is recommended for intermittent (blood sample)
or continuous (fiber optic) measurement of central venous
oxygen saturation (ScvO2), which indicates whether car-
diac output is appropriate to the metabolic conditions and
provides useful information for adaptation of treatment.
5- Central venous pressure should not be measured
because of the constraints of measurement and its
limits as a marker of preload and of preload
dependency (weak agreement).
6- In shock refractory to empirical treatment, cardiac
output as well as mixed venous oxygen saturation
(SvO2) or ScvO2 should be continuously monitored
(strong agreement).
7- We suggest pulmonary artery catheterization in
patients with refractory cardiogenic shock and right
ventricular dysfunction (weak agreement).
8- We suggest the use of a transpulmonary thermodilution
monitor/pulse wave analysis plus measurement
(continuous or intermittent) of mixed venous oxygen
saturation (SvO2) or ScvO2 when cardiogenic shock is
refractory to initial treatment, in the absence of
mechanical assistance and of predominant right
ventricular dysfunction (weak agreement).
9- Routine echocardiography (transthoracic and/or
transesophageal) should be used to identify the
cause of (cardiogenic) shock, for later hemodynamic
evaluations, and for the detection and treatment of
complications (tamponade) (strong agreement).
Area 4: management of blood pressure and cardiac output
in intensive care
1- A MAP of at least 65 mmHg should be reached
using inotropic treatment and/or vasopressor
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hypertension.
In analogy to septic shock, the target mean arterial
pressure should be titrated to 65–70 mmHg, as a higher
blood pressure is not associated with beneficial outcome
with the exception of previously hypertensive patients.
2- Norepinephrine should be used to restore perfusion
pressure during cardiogenic shock (strong agreement).
The only randomized study comparing two types of
vasopressors—norepinephrine and epinephrine—showed
that, for the same hemodynamic efficacy, epinephrine was
associated with a higher heart rate, more arrhythmia, and
lactic acidosis [11]. In a cohort study, De Backer et al. re-
ported a reduction in mortality with norepinephrine when
compared with dopamine [12]. Lastly, norepinephrine-
induced increase in blood pressure in patients with post-
MI CS is associated with an increase in cardiac index
without an increase in heart rate and with increased SvO2
and reduced blood lactate [13].
3- Epinephrine can be a therapeutic alternative to the
combination of dobutamine and norepinephrine,
but is associated with a greater risk of arrhythmia,
tachycardia, and hyperlactatemia (weak agreement).
In terms of hemodynamic effect, epinephrine clearly in-
creases cardiac output, essentially by a heart rate effect,
but is associated with severe hyperlactatemia of metabolic
origin that hampers interpretation of lactate as a marker
of the adequacy of tissue perfusion [14].
4- Dobutamine should be used to treat low cardiac
output in cardiogenic shock (strong agreement).
In terms of hemodynamic and/or metabolic endpoints,
compared with epinephrine, dobutamine results in less
arrhythmia, less myocardial oxygen consumption, and a
lower increase in lactate concentration [11]. Compared with
dopamine, the increase in cardiac output is less marked with
dobutamine, but at the cost of a greater drop in blood pres-
sure [15]. Dobutamine must be used at the lowest possible
dose, starting at 2 μg/kg/min. Its titration is based on cardiac
index and SvO2. Dopamine must never be used.
5- Phosphodiesterase inhibitors or levosimendan
should not be used first-line (strong agreement).
However, these drug classes, and in particular levosi-
mendan, can improve the hemodynamics of patients
with cardiogenic shock refractory to catecholamines.
There is a pharmacological rationale for the use of thisstrategy in patients on chronic beta-blocker treatment
(weak agreement).
CS refractory to catecholamines can be treated by perfu-
sion of phosphodiesterase inhibitors [16] or levosimendan
[17]. While these two drug classes improve macrocircula-
tory hemodynamics, only levosimendan appears to improve
prognosis [17]. Levosimendan improves myocardial per-
formance by increasing myofilament calcium sensitivity,
without raising intracellular calcium and AMP concentra-
tions. It therefore does not increase or has very little myo-
cardial oxygen consumption. There is a pharmacodynamic
rationale for the use of levosimendan in patients on chronic
beta-blocker treatment. In CS refractory to catecholamines,
it seems logical to consider the use of circulatory support
rather than increased pharmacological support.
Area 6: prehospital and emergency care
1- In prehospital care of shock without an obvious cause,
cardiogenic shock should be suspected, and 12-lead
ECG should be performed (strong agreement).
2- In prehospital care, high diastolic blood pressure
suggests a decrease in ventricular ejection evoking
hypovolemia or heart failure (strong agreement).
3- In prehospital care, in the absence of signs of acute
pulmonary edema or right ventricular overload, careful
volume expansion is called for (strong agreement).
4- In prehospital and emergency care, the vasopressor
of choice is norepinephrine (weak agreement).
5- There are no particular characteristics with regard
to indications for intubation and assisted ventilation,
except for right ventricular infarction (relative
contraindication) (weak agreement).
6- Coronary angiography should be performed
according to a defined protocol (call number, direct
admission, ideally presence of an intensivist,
post-procedure bed) (strong agreement).
7- Medical emergency call centers should transfer
patients to an expert center (strong agreement).
Area 7: cardiogenic shock and cardiac arrest
1- Because of its high prevalence, a cardiogenic cause
should routinely be sought using echocardiography
during post-cardiac arrest care (strong agreement).
Early mortality is seen in a large proportion of patients
admitted to intensive care after cardiopulmonary resus-
citation because of shock [18]. This post-cardiac arrest
shock comprises cardiogenic and vasoplegic compo-
nents, although myocardial failure is sometimes over-
looked, particularly when the cause of cardiac arrest is
non cardiac in origin. This myocardial failure occurs
early, is severe, generally resolves within 48 h, and is
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nent, the result of inflammation syndrome, which is well
documented in post-cardiac arrest [19]. Microcirculatory
anomalies are associated with this clinical picture [20].
2- In proven post-cardiac arrest cardiogenic shock,
especially in shockable rhythms, routine coronary
angiography is recommended (strong agreement).
Ischemic cardiopathy, in a setting of acute coronary
syndrome or chronic cardiopathy, is currently the leading
reason for cardiopulmonary resuscitation in the Western
world. Bearing this in mind, several authors have proposed
routine coronary angiography in the management of car-
diac arrest of presumed cardiac cause, so as to detect, and
if need be treat, acute coronary occlusion. Several studies
have reported that coronary angioplasty is performed in
between 26 and 50 % of cases at the initial phase of a car-
diac arrest (on the principle that angioplasty is performed
when acute coronary occlusion is deemed responsible for
the cardiac arrest). Contrasting with these high rates of
coronary occlusion, noninvasive strategies for detection of
acute coronary occlusion are, at present, disappointing.
ST-segment changes and troponin increase are insuffi-
ciently discriminatory compared with the potential benefit
of properly conducted coronary revascularization.
3- The existence or onset of post-cardiac arrest
cardiogenic shock is not a contraindication to
therapeutic hypothermia (strong agreement).
4- During post-cardiac arrest cardiogenic shock,
hyperthermia must be avoided (strong agreement).
Area 8: circulatory support
1- Intraaortic balloon counterpulsation should not be
used in cardiogenic shock in the setting of
myocardial infarction managed effectively and
quickly by angioplasty (weak agreement).
In the randomized multicenter IABP-SHOCK II trial
[4, 21], there was no significant difference in mortality at
day 30 (39.7 % in the intraaortic balloon counterpulsa-
tion group and 41.3 % in the control group, relative risk
0.96, 95 % confidence interval 0.79–1.17, p = 0.69) in
the total population or in any of the subgroups, in par-
ticular patients with systolic blood pressure <80 mmHg.
The final 12-month results of this cohort were recently
reported [22] as follows: 155 (52 %) of the 299 patients
in the intraaortic balloon counterpulsation group and
152 (51 %) of the 296 control patients had died (relative
risk 1.01, 95 % confidence interval 0.86-1.18, p = 0.91).
Complications were identical in the two groups. Accord-
ing to the ESC recommendation, intraaortic ballooncounterpulsation can be used in the case of revasculariza-
tion by thrombolysis or in the absence of initial revascu-
larization or if rescue therapy such as extracorporeal
membrane oxygenation, the Impella® device, or the Tan-
demHeart™ percutaneous ventricular assist device is not
available on site.
2- If temporary circulatory support is needed, the use
of peripheral extracorporeal membrane oxygenation
is preferred (strong agreement).
The veno-arterial extracorporeal membrane oxygenation
(ECMO) circuit, which comprises a centrifugal pump and
a membrane oxygenator, provides complete cardiopulmo-
nary support. ECMO reduces ventricular preload, but in-
creases ventricular afterload. ECMO is currently the
cheapest and longest-lasting device and the only device to
enable complete respiratory support in addition to circula-
tory support. It is easier to set up than TandemHeart™ or
Impella® 5.0. ECMO can be rapidly implemented at
bedside, even in the field, when a mobile ECMO unit is
used. Numerous studies have reported the use of
ECMO in refractory CS in the case of MI [22, 23] or
myocarditis [23–25], after cardiac surgery [26, 27] and
in the case of refractory cardiac arrest [28, 29]. There is
no meta-analysis or randomized trial that has assessed
prognosis after ECMO in CS. A single retrospective
study of before/after design [30] has shown an im-
proved prognosis after implementation of ECMO in
refractory CS in MI (mortality; 18/25, 72 % before
ECMO and 18/46, 39 % after, p = 0.003).
3- The Impella® 5.0 device can be used in the
management of cardiogenic shock complicating
myocardial infarction if the surgical team has
experience with its placement (weak agreement).
On the contrary, due to the limited blood blow obtained
with the Impella® 2.5 device, the latter is not recom-
mended for cardiac support during cardiogenic shock.
4- The creation of circulatory support mobile units to
set up veno-arterial ECMO in the field before
transfer of the patient to an expert center is
recommended (strong agreement).
When a CS patient’s clinical condition is deemed too
precarious to allow transfer without circulatory support,
a mobile unit should be used to set up ECMO quickly in
the department where the patient is treated before transfer
of the patient to the expert center. There is no meta-
analysis or randomized trial to date assessing this strategy.
Some retrospective studies have reported that this strategy
improved patient prognosis, demonstrating its feasibility
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managed in hospital.
Area 9: general treatments
1- In cardiogenic shock, ventricular resynchronization
is possible in cases of left-bundle branch block with
wide QRS complex (weak agreement).
ESC recommendations do not mention CS as an indica-
tion for resynchronization. Resynchronization has enabled
improvement of clinical condition and weaning from ino-
tropic agents in patients with severe acute heart failure
(NYHA class III-IV). In 15 CS patients with left-bundle
branch block, a German team showed that temporary
resynchronization of the left ventricle using a lead placed
in the coronary sinus (while maintaining atrioventricular
synchronous contraction using a right atrial lead) opti-
mized macrocirculatory parameters and reduced blood-
lactate concentration [31]. However, because of the
absence of literature data of high level of proof, its routine
use in CS patients cannot be recommended, because of
the risk of infectious and mechanical complications asso-
ciated with pacemaker implantation.
2- In patients with cardiogenic shock and arrhythmia
(atrial fibrillation), restoration of sinus rhythm, or
slowing the heart rate if restoration fails, can prove
useful (strong agreement).
3- In cardiogenic shock, antithrombotic drugs at the
usual dosages should be used, in their recognized
indications, bearing in mind that the hemorrhagic
risk is greater in this situation (strong agreement).
The only exception is that antiplatelet agents such as
clopidogrel or ticagrelor should be given after elimination
of a surgical complication, i.e., not in a prehospital setting.
4- Nitrovasodilators should not be continued or
introduced during cardiogenic shock (strong
agreement).
5- When cardiogenic shock is associated with
pulmonary edema, diuretics can be continued or
introduced (weak agreement).
6- Beta-blockers should not be used during cardiogenic
shock (strong agreement).
7- In ischemic cardiogenic shock, the hemoglobin level
should be maintained at around 10 g/dL during the
acute phase (weak agreement).
During the very acute phase of cardiogenic shock in
which oxygen delivery is low and cardiac output is insuf-
ficient to meet metabolic demand, it may be useful to
increase hemoglobin levels. Nevertheless, as soon ascardiogenic shock is resolved, the transfusion trigger
should to 7 g/dL.
8- When cardiogenic shock is not ischemic in origin,
the hemoglobin level should be maintained above
8 g/dL (weak agreement).
Area 10: surgery and cardiogenic shock
1- In adults presenting severe aortic stenosis associated
with cardiogenic shock, the aortic stenosis should be
managed, probably by valvuloplasty and if need be,
under ECMO (strong agreement).
In a CS patient presenting with severe aortic stenosis,
and according to international recommendations [32],
treatment of the aortic obstacle should be envisaged. The
surgical treatment of severe aortic stenosis complicated by
CS carries a high surgical risk. Literature data evaluating
surgical results in this indication are scarce [33]. Surgeons
are often disinclined to operate on these hemodynamically
unstable patients. To reduce this surgical risk, aortic valvu-
loplasty-“pending” surgery can be envisaged. Literature
studies only relate to retrospective cohorts with a limited
number of patients in which the results of aortic valvulo-
plasty in CS patients are evaluated. In these studies, hos-
pital mortality following aortic valvuloplasty in CS patients
range between 42 and 57 %. Serious complications occur
in 10 % of cases, and valvular stenosis associated with clin-
ical deterioration recurs in 6 to 12 months.
2- In adults presenting with severe aortic stenosis
responsible for cardiogenic shock, valve repair/
replacement should not be performed by first-line
transcatheter aortic valve implantation (weak
agreement).
Percutaneous valve placement is currently contraindi-
cated in CS patients, although a retrospective study with
encouraging results has been published (hospital mortality
19 %) [34].
3- In adults presenting with aortic or mitral insufficiency
responsible for cardiogenic shock, the valve should be
replaced without delay (strong agreement).
4- In adults presenting with mitral insufficiency
responsible for cardiogenic shock, intraaortic balloon
counterpulsation and vasoactive/cardiac drugs can
be used to achieve stabilization pending surgery,
which should be performed promptly (<12 h)
(strong agreement).
5- In the case of interventricular communication, the
patient should be transferred to an expert center for
assistance and to discuss surgery (strong agreement).
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alternative to dobutamine in second-line treatment
of cardiogenic shock after cardiac surgery (weak
agreement). Levosimandan could be used as a
first-line treatment of cardiogenic shock after
coronary bypass surgery (weak agreement).
Because they do not act on beta-receptors, these two
drugs are potentially useful in cardiogenic management.
However, because of their prolonged and potential vasodila-
tatory actions, these two drugs should be handled with care.
Levosimendan is the only drug for which a randomized
study indicates a significant reduction in mortality in treat-
ment of CS after coronary artery-bypass surgery, in com-
parison with dobutamine. A meta-analysis on levosimendan
and cardiac surgery also indicated a significant reduction in
mortality, although the analysis indiscriminately included
studies in which levosimendan was administered prophylac-
tically or before or during surgery and studies in which ad-
ministration of levosimendan was initiated after surgery in
response to CS [35]. Other studies of very low level of proof
did not find any reduction in mortality with levosimendan
after cardiac surgery (mixed cohort of patients with coron-
ary artery-bypass surgery and valve replacement). It there-
fore appears possible to administer levosimendan to treat
CS after coronary artery-bypass surgery.
7- It is possible to use milrinone as first-line treatment to
increase inotropism in cardiogenic shock associated
with right ventricular failure (weak agreement).
8- It is possible to administer levosimendan after
coronary artery-bypass surgery as first-line
treatment of cardiogenic shock after cardiac
surgery (weak agreement).
Area 11: management of cardiac drug toxicity leading to
cardiogenic shock
1- Knowledge of the causal mechanism(s) (hypovolemia,
vasodilation, altered contractility) is essential for
adaptation of treatment. Emergency echocardiography
is mandatory, followed by continuous measurement of
cardiac output and SvO2 (strong agreement).
Broadly speaking, a distinction should be drawn be-
tween toxicity with hypokinesis in cardiogenic shock and
vasoplegic shock. The latter is generally treatable using
vasopressor drugs (norepinephrine) and volume expan-
sion. The possibility of mixed forms or of vasoplegic forms
progressing to hypokinesis should not be overlooked.
2- When there is cardiac drug toxicity in a state of
shock, emergency echocardiography is required to
detect a hypokinetic state (strong agreement).3- Cardiac toxicity (particularly associated with
sodium channel blockers, calcium inhibitors, and
beta-blockers) in a state of shock should prompt
transfer of the patient to an expert center with
experience in ECMO, especially if echocardiography
reveals a hypokinetic state. In shock that is
refractory or progresses rapidly and occurring in a
center without ECMO, use of a circulatory support
mobile unit should be considered. Ideally, ECMO
should be implemented before onset of other organ
failures (liver, kidney, ARDS) and in all cases before
cardiac arrest. Vasoplegic shock alone is not an
indication for ECMO (strong agreement).
4- Heart failure necessitates the addition of dobutamine
to norepinephrine or the use of epinephrine,
bearing in mind its side effects (lactic acidosis)
(strong agreement).
5- Adjuvant treatments such as glucagon
(beta-blockers), insulin therapy (calcium inhibitors),
and lipid emulsion (lipid-soluble cardiotoxic local
anesthetic) should be initially used in association
with vasopressor/inotrope agents (strong
agreement). Medical supportive treatment should
not delay use of ECMO in case of refractory shock
(weak agreement).
6- The administration of molar sodium bicarbonate
(doses fractionated from 100 to 250 mL up to a
maximum total dose of 750 mL) is indicated in toxic
shock with intraventricular conduction
abnormalities (wide QRS complex), together with
other treatments (strong agreement).
Area 12: cardiogenic shock complicating end-stage
heart disease
1- Patients with severe chronic heart disease should
be assessed for their heart transplant eligibility
in a center equipped for this intervention
(strong agreement).
2- A patient with end-stage decompensated heart
failure considered eligible for heart transplantation
should be rapidly managed in the expert center that
conducted the assessment (strong agreement).
3- ECMO/extracorporeal life support is indicated as
first-line treatment in the case of progressive or
refractory shock (persistent lactic acidosis, low
cardiac output, high doses of catecholamines, kidney
and/or liver failure) and of cardiac arrest without
“no flow” in patients with advanced chronic
heart disease with no contraindication for heart
transplantation (strong agreement).
4- In progressive or refractory cardiogenic shock in a
patient hospitalized for decompensated heart failure
in a center without circulatory support, prompt use
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veno-arterial ECMO followed by transfer of the
patient on ECMO to an expert center is
recommended (strong agreement).
Area 13: post-shock treatment
1- Once the acute phase of cardiogenic shock has been
managed, appropriate oral treatment of heart failure
should be implemented and closely monitored
(strong agreement).
2- Very early after withdrawal of vasopressor drugs,
treatment with beta-blockers, angiotensin-
converting enzyme inhibitors, and aldosterone
antagonists should be introduced to improve
survival by reducing the risk of arrhythmia and of
recurrence of an episode of heart failure
(strong agreement).
Once shock is treated, management of the patient
should follow the most recent guidelines for treatment of
chronic heart failure. Treatment is to be introduced early,
upon withdrawal of vasopressor drugs at small doses that
are progressively raised. In certain cases, introduction of
treatment is poorly tolerated, and temporary vasopressor
reintroduction may be necessary.
Area 14: other etiologies
1- Patients with acute heart failure or cardiogenic
shock associated with myocarditis should be
transferred to an expert center, on ECMO if
necessary (strong agreement).
2- Bromocriptine treatment should be considered in
cardiogenic shock complicating peripartum
cardiomyopathy after discounting pre-existing or
genetic heart disease (weak agreement).
3- Before making a diagnosis of stress cardiomyopathy,
coronary artery disease should be discounted by an
imaging technique (coronary angiography or
computed tomography) and ventricular imaging
(echocardiography or ventriculography or magnetic
resonance imaging) (strong agreement).
4- Treatment of severe stress cardiomyopathy is based
on management of any predisposing factor and
should be symptomatic, based on restoring a
favorable myocardial energy balance
(strong agreement).
5- In stress cardiomyopathy, a decrease in dosage of
inotropic agents or even their discontinuation is
recommended, provided circulatory flow rate can be
controlled by mechanical means in severe shock
such as: intraaortic balloon counterpulsation and
short-term circulatory support (ECMO,TandemHeart™, centrifugal pump). As prognosis is
good and reversibility is often quick, the risk-benefit
ratio must be evaluated by an expert center
(strong agreement).
Area 15: medical care pathway
This is probably the most important aspect of our expert
panel’s recommendations. CS is a rare disease for which
management requires a multidisciplinary technical plat-
form and specialized and experienced medical teams.
1- From emergency to rehabilitation, the patient must
be managed along a specialized medical care
pathway suited to the actual or potential seriousness
of his or her condition (strong agreement).
2- This medical care pathway must be fully recognized
by all those involved (emergency medical services,
emergency room, cardiology, intensive care, cardiac
surgery departments). In particular, an expert-center
24/7 telephone line offering specialist advice must be
available (strong agreement).
3- Official recognition by the regional health
authorities of expert centers is recommended. Each
expert center must be able to provide, at the same
site, skills in a variety of disciplines (medical and
interventional cardiology, anesthesia, thoracic and
vascular surgery, intensive care, radiology including
for interventional vascular procedures, circulatory
support mobile unit) (strong agreement).
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